Searched for
GSK PLC
Haleon to invest Rs 2,000 crore to set up first India plantHaleon is investing Rs 2,000 crore to build its first manufacturing plant in Pithampur, India. This move sharpens its focus on India, a fas...- Bombay HC backs GSK in Paxil trademark row against Shreya Life SciencesThe Indian subsidiary of the UK-based GSK PLC had urged the court to cancel the mark used by the local company in pharmaceutical and medici...
- Bharat Biotech, GSK join hands to develop vaccine for severe diarrhoeaBharat Biotech and GSK plc have partnered to develop a vaccine for Shigellosis, a severe bacterial diarrhea. The altSonflex1-2-3 vaccine ca...
- GSK to buy Canada's Bellus Health for $2 blnThe acquisition gives GSK access to camlipixant, which is in late-stage development for the first-line treatment of adult patients with ref...
- GSK preparing to start Rs 28,000 crore stake sale in HULET Now, quoting agencies, said GSK PLc is likely to start the discussion of its stake in the next few days.
- HUL acquires Horlicks from GSK for Rs 3,045 croreGSK brands like Horlicks, Boost, Maltova and Viva have come to HUL’s portfolio as part of the merger.
- NCLT clears GSK-HUL merger, paves way for GSK Plc’s exit through huge block dealOfficials aware of the developments say Morgan Stanley is readying the share sale process.
- GSK weighs multi-billion New Year bonanza by cashing out HUL stakeThe company is hoping to cash out what will be a near 6 per cent stake in HUL.
- HUL to pour Horlicks into its portfolio with GSK dealUnilever edged past Nestle, the world’s largest food and drinks company, in a closely fought battle.
- Minority investors to gain from GSK’s strategic reviewGSK CH’s sales are down from Rs 4,683 crore in FY14 to Rs 3,986 crore in FY17.
- GSK may put iconic Horlicks for sale to fund $13-billion Novartis dealGSK is initiating a strategic review of Horlicks and its other consumer healthcare nutrition products to support funding the Novartis deal.
- Continued pressure on Horlicks, destocking negatively impacted nutrition business: GSK
- GlaxoSmithKline Consumer Healthcare Ltd India-Novartis deal won't affect business in IndiaGlaxoSmithKline Consumer Healthcare today said the global deal between GlaxoSmithKline Plc and Novartis won't affect its business in India.
- GlaxoSmithKline to spend $1 billion to raise stake in Indian pharma unitGSK said that it was looking to buy a 24% stake in the pharmaceuticals subsidiary for about $1billion or Rs 6,400 crore.
- India is a strategically important market for us: David Redfern, GSK Plc"As India develops, there will be a growing focus on more medicines and vaccines which are required," Redfern said.
- Parent offer talk spurs GSK PharmaIt may be the season of open offers by MNCs. GlaxoSmithKline Consumer started it earlier this year, followed by Unilever and, the latest, M...
- GlaxoSmithKline Consumer Healthcare signs a brandsswap deal with GSK PharmaceuticalsThe cross-functional collaboration deal, to swap select brands and independently market, sell and distribute them, is one of the four lever...
- Want to make stake raising offer attractive for GSK Consumer shareholders: David Redfern, GSK"We have been obviously launching the offer to acquire up to 75% and what we think is hopefully an attractive premium for the current share...
- ‘Productivity of global pharma R&D pipelines has fallen’The Indian arms of most global pharma giants have so far remained under-sized, rather off their parent’s radar for sometime now. But are th...
- GSK, TCS to set up global centre in MumbaiGlaxoSmithKline (GSK) Plc and Tata Consultancy Services (TCS) on Tuesday announced an agreement to establish a global drug development supp...
Load More
